Merck's (MRK) Co-formulation Therapy Fails Lung Cancer Study

admin March 17, 2023
0 Comments

This article was originally published on Nasdaq

Merck MRK provided an update on the open-label arm of the phase II KeyVibe-002 study, which evaluated an investigational co-formulation MK-7684A in patients with metastatic non-small cell lung cancer (NSCLC).

Categories: Nasdaq Stocks

Responses

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Invite this member to nests
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .